Breaking from tradition. Ignite the path to a cure.

An Interview with Chief Technology Officer Dima Shvartsman, Ph.D

May 27, 2021 10:52:26 AM / by David Deems

We sat down with CTO Dima Shvartsman, Ph.D to speak about his role within the company and the exciting potential for human health research using Cellaria's cell lines and cell models. 


Hi Dima, can you tell us a bit about Cellaria?

 

Cellaria provides actionable disease cell models and stem cells for diseases that are either hard to treat or in research areas where legacy cell lines currently fail or don’t even exist. We provide a foundation for more reproducible, clinically relevant research, opening the door to powerful personalized disease treatment.

 

Legacy cell lines have been long suspected, and more recently, often proven to be contaminated, irreproducible, and unactionable for patient outcomes. They are plagued by genetic drift, clonal takeover, spontaneous mutations and other issues stemming from decades-long culturing. Disease investigators and drug developers require high-fidelity, patient-specific cell models to ensure their drug research produces actionable, and insightful, data for better pre-clinical decision making. Cellaria models fulfil this need.

 

Can you tell us a bit about your background? What was your journey to working at Cellaria?

 

I am trained as a molecular cell biologist for my graduate degree and then made a pivot to bioengineering, drug and cell delivery, disease modeling during my postdoctoral work. More recently, I’ve managed a large and diverse group of researchers in stem cell developmental and translational biology. A broad set of skills and research interests led me to Cellaria.

 

Can you tell us a bit about your role at Cellaria ?

 

In my current role I have several responsibilities: I manage all scientific work and provide both strategic and daily guidance to the group, plan both the R&D and product development. I take inquiries from prospective clients, manage project communications and troubleshooting with customers, and interact with BD inquiries. I also review scientific literature and brainstorm new ideas.

 

What excites you most about the Cellaria technology?

 

I am most excited about the ease with which the technology can be deployed in a multitude of ways for research and its deep platform potential. Cellaria’s technology has unlimited potential for science and translational findings for healthy and disease models. Deploying the technology to applications in pre-clinical and translational research will create a lot of possibilities for innovation in human health. 

 

Where have you worked previously?

 

I worked as a postdoctoral researcher at Harvard School of Engineering, followed by postdoctoral work at Brigham Women’s. Later I served as a Senior Research Manager at Harvard Stem Cell Institute for two years before joining Cellaria. 

 

If you could say one thing to potential customers of Cellaria, what would it be? 

 

Our products and services offer a robust and scalable disease or healthy tissue model to any researcher who requires them. Cellaria’s certified disease models can reduce cost and time requirements in the preclinical stage and accelerate drug development in personalized therapeutics. 

 

What do you like to do in your free time? 

 

I have many hobbies, among them reading, playing tennis, riding a bicycle, restoring Japanese swords, collecting stamps etc. I’m also very busy with raising four kids and being with my family. I enjoy networking both in professional and casual settings, and I like being involved in communal activities where I live.



Thank you Dima!  

 

Topics: Insider, Interview

David Deems

Written by David Deems